Europe's AI Act Is Not a Burden — It Is a Competitive Advantage

The EU AI Act generates complaints from AI companies that are, in many cases, legitimate. Compliance is expensive. The risk classification framework is complicated. The documentation requirements for high-risk AI systems are onerous. For a small startup trying to move fast and build product, the regulatory overhead imposed by the EU AI Act is real and non-trivial. And yet we believe the AI Act represents, on balance, a significant competitive advantage for European AI companies — particularly those building enterprise AI products for regulated industries. Here is our argument.

What the AI Act Actually Does

The EU AI Act, which entered into force in August 2024 and is being implemented on a phased schedule through 2026, is the world's first comprehensive AI regulatory framework. It takes a risk-based approach, classifying AI applications by the potential harm they could cause and imposing proportional obligations on companies that deploy them. Unacceptable-risk applications — biometric mass surveillance, social scoring systems, AI systems that exploit vulnerable populations — are prohibited outright. High-risk applications — AI used in healthcare diagnostics, hiring decisions, credit scoring, critical infrastructure control, and similar contexts — are subject to extensive pre-market conformity assessment, ongoing monitoring, and documentation requirements. Limited-risk applications face transparency obligations. And minimal-risk applications are largely unregulated.

The practical impact of the AI Act on most AI companies is concentrated in the high-risk tier. For an AI company building a general-purpose language model or a consumer recommendation system, the AI Act imposes minimal direct obligations beyond transparency requirements. For an AI company building diagnostic support tools for radiologists, automated hiring screening systems, or credit risk assessment platforms, the requirements are substantial: risk management documentation, data governance procedures, technical robustness testing, human oversight mechanisms, and mandatory incident reporting.

These requirements impose genuine costs. A startup building a high-risk AI application for the European market must invest in legal and compliance expertise, documentation infrastructure, and testing protocols that its competitors operating in less regulated markets may not yet need. In the short term, this compliance overhead disadvantages European AI startups in their capital allocation — a portion of the seed round that might otherwise go into engineering or go-to-market must go into compliance.

The Brussels Effect and the Global Compliance Premium

The costs described above are real, but they ignore the most important dynamic in global AI regulation: the Brussels Effect. The Brussels Effect — the documented tendency for EU regulations to become de facto global standards because multinational companies find it easier to adopt a single global compliance standard than to maintain separate regulatory compliance postures for different jurisdictions — is already operating in AI.

Microsoft, Google, Amazon, and dozens of smaller AI companies are already building AI Act compliance capabilities into their products, not because they believe the regulation is optimal, but because they sell to European enterprises that require it. As these compliance frameworks are built into the technical architecture of AI products, they become default features that are deployed globally rather than just in Europe. The European standard is becoming the global standard by economic gravity.

For European AI companies that have built AI Act compliance into their products from day one, this convergence is a commercial advantage. When a pharmaceutical company, a financial institution, or a healthcare system in the United States, Japan, or Singapore is evaluating AI vendors for a high-risk application, the European company that can demonstrate conformity with the EU AI Act — the most rigorous AI regulatory standard currently in existence — has a credibility advantage over competitors whose compliance posture is less developed. The compliance investment that felt like a burden at the seed stage becomes a sales asset in the enterprise go-to-market.

The Regulated Enterprise Market Is the Most Valuable AI Market

The most attractive segments of the enterprise AI market are, by definition, the regulated ones. Healthcare AI — drug discovery, clinical decision support, medical imaging analysis — is subject to medical device regulation, not just the AI Act, but the intersection of AI regulatory compliance and medical device regulatory compliance is exactly where the most defensible commercial positions in AI will be built. Financial services AI — credit underwriting, fraud detection, algorithmic trading, insurance pricing — is subject to financial regulation in every jurisdiction, and AI systems that demonstrate explainability, fairness, and auditability are substantially easier to deploy through the procurement processes of regulated financial institutions than those that do not.

These regulated markets are large, have structurally high willingness to pay, and have long switching cost dynamics that create durable customer relationships once products are deployed. The enterprise healthcare and financial services AI market in Europe alone is worth hundreds of billions of euros over the next decade. Globally, it is multiples of that. The AI companies that are built for regulatory compliance — that have explainability, auditability, and data governance as core architectural features rather than compliance bolt-ons — will have a substantial advantage in serving these markets.

European AI companies building for regulated enterprises have an additional advantage: regulatory relationships. Companies that have engaged with the European AI regulatory process — that have participated in regulatory sandboxes, contributed to consultation processes, and built relationships with national supervisory authorities — have a depth of regulatory intelligence and a network of regulatory relationships that their competitors in less regulated markets will take years to develop. When the US, UK, or Asian regulators inevitably develop their own AI regulatory frameworks, European companies with established AI regulatory expertise will be better positioned to navigate these new requirements than companies that have never operated in a serious regulatory environment.

The Compliance Infrastructure Market Itself

Beyond the advantage that the AI Act confers on individual AI companies building compliant products, the regulation creates an entirely new market: AI compliance infrastructure. Companies need tools to document AI system development, track data provenance, conduct bias testing, implement human oversight mechanisms, and generate the audit trails required by the AI Act. This market did not exist before the AI Act, and it is growing rapidly.

European companies building AI compliance infrastructure have a structural first-mover advantage in this market. They are closest to the regulatory process, most familiar with the specific requirements of the Act, and most credible to European enterprises evaluating compliance tools. As the AI Act's requirements scale up — with high-risk application obligations coming into full effect in 2026 and general-purpose AI model requirements phasing in over the same period — the demand for AI compliance tooling will grow substantially.

We are actively evaluating AI compliance infrastructure companies at the seed stage. The companies that build category-defining positions in this market over the next two to three years — establishing themselves as the standard tools for AI documentation, testing, and governance in European enterprises — will benefit from strong network effects, high switching costs, and a regulatory moat that will be difficult for late entrants to replicate.

What This Means for Our Investment Strategy

Our view of the AI Act as a competitive advantage rather than a burden is reflected in how we approach AI investment decisions. We actively prefer AI companies that are building for regulated enterprise markets, that have compliance as a core architectural feature rather than an afterthought, and that have founders with genuine understanding of the regulatory context in which they are operating. We are skeptical of AI companies that treat the AI Act primarily as a cost to be minimised, because we believe this posture indicates a misunderstanding of where the long-term value in enterprise AI will be created.

We are also actively looking for AI companies that are building compliance infrastructure — the tools, frameworks, and services that help other AI companies demonstrate AI Act conformity. This category is underinvested relative to its importance, and the companies that establish credible positions in it over the next two years will benefit from the same regulatory tailwinds that are driving the AI Act compliance investment wave.

For founders building in enterprise AI for regulated industries, or building the compliance infrastructure that enables AI deployment in those industries, we believe the current moment is the best opportunity for seed-stage investment in the space. The regulatory context is established and visible, the commercial demand is building, and the technical and regulatory expertise required to compete is scarce enough to create genuine moats for early entrants. Get in touch if you are building in this space — we are eager to learn about your approach.